Your session is about to expire
← Back to Search
Belatacept for Immunosuppression in Kidney Transplant Recipients
Study Summary
This trial is testing if a patient's DNA can predict if they will have a successful kidney transplant with just one immunosuppressive drug, instead of the multiple drugs typically required.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 4 trial • 3 Patients • NCT02078193Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My current kidney transplant is affected by BK virus.I am not pregnant, breastfeeding, nor planning to become pregnant during the trial.I've been on Belatacept for my kidney with stable function for 3 months.I have severe liver problems.My organ transplant is from a non-identical donor.My kidney function has been stable for the last 3 months.I have had a kidney transplant in both of my kidneys.My body does not have specific antigens against a donor.I am over 18 and have received a kidney transplant.I had a kidney transplant more than 9 months ago.I have had severe or frequent rejection episodes in the last 3 months.I have had an organ transplant that is not a kidney.
- Group 1: Immunosuppression Taper
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies for prospective participants in this experiment?
"Yes, according to clinicaltrials.gov records this medical trial is currently enrolling candidates with the original posting taking place on July 28th 2021 and edits being made as recently as December 30th 2021."
Are there any prior studies that have incorporated Belatacept in their research?
"Currently, 12 studies for Belatacept are active with 1 trial in the third stage. San Francisco is a major centre for this medication's clinical trials; however, there are 48 total locations across America running these experiments."
What risks are associated with the usage of Belatacept?
"The safety of Belatacept was assessed at 3, denoting its Phase 4 classification and consequently approved status."
How many participants are taking part in this clinical trial?
"Affirmative. According to the data posted on clinicaltrials.gov, this study that was published on July 28th 2021 is still recruiting patients and has opened 1 site for enrollment of 25 participants."
Does this experiment herald a new era of research?
"Belatacept has undergone a series of trials since its initial study in 2018, which was sponsored by Rho Federal Systems Division, Inc. Following the first Phase 1 trial involving 6 participants, Belatacept received approval for widespread use and currently there are 12 active investigations underway across 8 different nations."
Share this study with friends
Copy Link
Messenger